Theraly Fibrosis, a TEDCO portfolio company, awarded $3.9 Million SBIR Phase II grant to support the development of TLY012 for Chronic Pancreatitis
Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases today announced the company has been awarded a Small Business Innovation Research (SBIR) Phase II grant by the National Institutes of Health (NIH) in the amount of $3.9 million to support development of TLY012 for treatment of chronic pancreatitis.
About TEDCO
TEDCO, the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland. Learn more at www.tedcomd.com.
Tammi Thomas, President, TEDCO, tthomas@tedcomd.com
Rachael Kalinyak, Associate Director, Marketing & Communications, TEDCO, rkalinyak@tedcomd.com